Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial.
暂无分享,去创建一个
M. Taron | B. Massuti | C. Camps | C. Queralt | R. Porta | T. Morán | M. Majem | F. Cardenal | R. Rosell | C. Mayo